Home › Duchenne Muscular Dystrophy › NCT05412394
Once Weekly Infant Corticosteroid Trial for DMD
RecruitingPhase 4
Phase-2 Trial of 5mg/kg/Week Prednisolone in Young Boys With DMD
Who can join
1 Month – 30 Months · Men
Full eligibility criteria
Inclusion Criteria: * Subjects ages 1 month through 30 months * Weakness consistent with Duchenne on exam, creatine kinase ≥ 20 times the upper limit of normal, and genetic mutation known to be causative for DMD. Exclusion Criteria: * Prior treatment with Glucocorticosteroids
About the study
The hypothesis tested here is that a lower dose of intermittent oral corticosteroids (5mg/kg/week) will be equally effective to the 10mg/kg/week dose.
What is being tested
- Prednisolone (drug)
Sponsor: Anne M. Connolly · Participants: 26 · Started: Apr 30, 2021
Contact the study team
- Sara Marshall · Phone: 614-355-3508
- Kevin Warf · Phone: 614-355-2765
Official record on ClinicalTrials.gov — NCT05412394
Locations in the U.S.
| Illinois | Lurie Children's Hospital of Chicago, Chicago |
| Ohio | University of Cincinnati, Cincinnati Nationwide Children's Hospital, Columbus |
| Texas | University of Texas Southwestern, Dallas |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.